Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
- PMID: 23158500
- DOI: 10.1016/j.crohns.2012.10.015
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
Abstract
Background: Metabolic risk factors are associated with non-alcoholic fatty liver disease (NAFLD), but they are less frequent in inflammatory bowel disease (IBD).
Aim: This study evaluates the frequency of NAFLD and its risk factors among IBD patients including anti-TNF-α therapy.
Methods: IBD patients who underwent abdominal imaging from January, 2009 to December, 2010 were analyzed in this nested, case-controlled study. IBD patients with NAFLD by imaging were compared with those who had no evidence of NAFLD (control).
Results: Among 928 IBD patients, 76 (8.2%) had evidence of NAFLD by imaging, and were compared to 141 patients without NAFLD evaluated (study: control ratio=~1:2). NAFLD patients were older (46.0 ± 13.3 vs. 42.0 ±14.1 years; p=0.018) and had a later onset of IBD compared to the control group (37.2 ± 15.3 vs. 28.7 ± 23.8 years; p=0.002). Metabolic syndrome was present in 29.0% of NAFLD patients, with a median Adult Treatment Panel risk factor of 2 [Interquartile range 1,3]. Patients not receiving anti-TNF-α therapy had a higher occurrence of NAFLD (p=0.048). In multivariate analysis, hypertension (OR=3.5), obesity (OR=2.1), small bowel surgeries (OR=3.7), and use of steroids at the time of imaging (OR=3.7) were independent factors associated with NAFLD.
Conclusion: NAFLD occurred in 8.2% of the IBD population. NAFLD patients were older and had a later onset of IBD disease. IBD patients develop NAFLD with fewer metabolic risk factors than non-IBD NAFLD patients. It is also less common among patients who received anti-TNF-α therapy.
Keywords: ASA; ATP; Adult Treatment Panel; Anti-TNF-α therapy; CD; Crohn's disease; Fatty liver; HDL; IBD; Inflammatory bowel disease; LDL; MP; NAFLD; NASH; PEM; PSC; Risk factors; TG; TNF; TSH; UC; aminosalicylic acids; high density lipoprotein; inflammatory bowel disease; low density lipoprotein; mercaptopurine; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; primary sclerosing cholangitis; protein energy malnutrition; thyroid stimulating hormone; triglycerides; tumor necrosis factor; ulcerative colitis.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.World J Gastroenterol. 2019 Oct 7;25(37):5676-5686. doi: 10.3748/wjg.v25.i37.5676. World J Gastroenterol. 2019. PMID: 31602167 Free PMC article.
-
Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.Medicina (Kaunas). 2023 Nov 1;59(11):1935. doi: 10.3390/medicina59111935. Medicina (Kaunas). 2023. PMID: 38003983 Free PMC article.
-
Hepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: A retrospective analysis.Saudi Med J. 2025 Jan;46(1):52-58. doi: 10.15537/smj.2025.46.1.20240758. Saudi Med J. 2025. PMID: 39779365 Free PMC article.
-
Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis. 2019 Oct 18;25(11):1764-1772. doi: 10.1093/ibd/izz043. Inflamm Bowel Dis. 2019. PMID: 30918952
-
The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease.Nutrients. 2021 Aug 13;13(8):2772. doi: 10.3390/nu13082772. Nutrients. 2021. PMID: 34444932 Free PMC article. Review.
Cited by
-
Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Inflamm Bowel Dis. 2021 May 17;27(6):947-955. doi: 10.1093/ibd/izaa189. Inflamm Bowel Dis. 2021. PMID: 32780094 Free PMC article.
-
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.World J Gastroenterol. 2016 Sep 14;22(34):7727-34. doi: 10.3748/wjg.v22.i34.7727. World J Gastroenterol. 2016. PMID: 27678354 Free PMC article. Review.
-
Shared biomarkers and immune cell infiltration signatures in ulcerative colitis and nonalcoholic steatohepatitis.Sci Rep. 2023 Oct 28;13(1):18497. doi: 10.1038/s41598-023-44853-6. Sci Rep. 2023. PMID: 37898694 Free PMC article.
-
Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.World J Gastroenterol. 2013 Nov 14;19(42):7327-40. doi: 10.3748/wjg.v19.i42.7327. World J Gastroenterol. 2013. PMID: 24259964 Free PMC article. Review.
-
Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.Int J Mol Sci. 2024 Mar 14;25(6):3278. doi: 10.3390/ijms25063278. Int J Mol Sci. 2024. PMID: 38542249 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous